ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), which accounts for 15% of all breast cancers, is characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, which means that TNBC patients do not benefit from hormonal therapy or trastuzumab, which targets HER2 [2-4].